Introduction {#Sec1}
============

From 1998, the Japanese Gastric Cancer Association (JGCA) began conducting a nationwide gastric cancer registration project by using electronic data collecting systems. Detailed survival analyses of 8851 patients with primary gastric cancer treated in 1991 were reported in 2006 \[[@CR1]\]. However, this nationwide registry was suspended because of several issues such as the operation of the Act Concerning Protection of Personal Information, revision of the JGCA classification for gastric cancer, and rapid changes in the information technology (IT) environment at the member hospitals. After a period of 10 years in which the program was inactive, the registration committee of the JGCA started a new registration program to collect anonymized data simply, correctly, and quickly, in 2008 \[[@CR2], [@CR3]\]. Based on this program, we investigated the survival outcomes of patients with primary gastric cancer treated in 2001.

Subjects, materials, and methods {#Sec2}
================================

In the 2008 JGCA nationwide registration program, approximately 50 data items, including surgical procedures, pathological diagnoses, and prognoses, for patients with primary gastric carcinoma surgically treated in 2001 were collected retrospectively in 2008 by using custom-made software. This software could be downloaded from the JGCA website. The JGCA member hospitals could participate in this project voluntarily.

The registration data of this system are listed in Table [1](#Tab1){ref-type="table"}. Definition and documentation of the items were based on the Japanese (JGCA) *Classification of gastric carcinoma, 13th edition* \[[@CR4], [@CR5]\] and the International Union Against Cancer (UICC) *TNM Classification of malignant tumors, 5th edition* \[[@CR6]\]. These two classifications were not compatible with each other and items could not be converted automatically. The JGCA T-category was identical to the TNM classification. On the other hand, in the JGCA classification, peritoneal metastasis and liver metastasis were individually recorded as P- and H-categories, both of which could be translated into the M-category in the TNM classification. Intraoperative peritoneal washing cytology (CY) was an independent category in the JGCA classification. The JGCA N-category was defined by the anatomical extension of lymph node metastasis in association with the location of the primary tumor, while the TNM N-category was defined by number of metastatic regional lymph nodes. Items that are compatible in the JGCA classification and the TNM classification, and items that are not compatible are listed in Table [2](#Tab2){ref-type="table"} for convenience.Table 1Registration dataCategoryItemPersonal informationName of hospital, serial no., case no., ID no.^a^, age, sexFollow-upDate of follow-up, survival situation, causes of deathSurgeryDate of operation, approach, operative procedure, LN dissection (D), organs resected together with stomach, type of reconstructionPathologyAnatomical subsite, macroscopic type, size of tumor, histological type, depth of tumor invasion, ly, v, number of dissected LNs, number of metastatic LNs, N, PM/DM, CYJGCA final diagnosisDepth of tumor invasion, adjacent structure involved, fN, H, P, M, curability, stageUICC TNM categoriesT, N, M, stage*LN* lymph node, *ly* lymphatic invasion, *v* venous invasion, *N* extent of LN metastasis (JGCA), *PM/DM* involvement of proximal and distal margin, *CY* peritoneal cytology, *fN* extent of LN metastasis (final diagnosis), *H* liver metastasis, *P* peritoneal metastasis, *M* distant metastasis, *JGCA* Japanese Gastric Cancer Association, *UICC* International Union Against Cancer^a^ID no. was not exported to the registration data set Table 2Compatibility to convert JGCA classification to TNM classificationCategoryJGCA 13th ed.TNM 5th ed.CompatibilityT1--40--4CompatibleN00Identical1--31--3IncompatibleM^a^00Compatible11CompatibleH0None1M1CompatibleP0None1M1CompatibleCY0None1NoneStageIAIAIdenticalIB, II, IIIA, IIIB, IVIB, II, IIIA, IIIB, IVIncompatibleLymphatic invasionly0L0Identically1--3L1CompatibleVenous invasionv0v0Identicalv1--3v1CompatibleNonev2Histological typingDifferentiated typeG1--2CompatibleUndifferentiated typeG3--4CompatibleResidual tumorResection A--CR0--2Incompatible^a^JGCA M-category is defined as distant metastases other than peritoneal, liver, or cytological metastases

After the patients' data were entered with the data entry software, the patients' names and other personal information were removed from the exporting data set for privacy protection. A compact disk containing the linkable anonymous data was then mailed to the JGCA data center, located at Niigata University Medical and Dental Hospital. The accumulated data of the patients were reviewed and analyzed by the JGCA registration committee. One- to 5-year survival rates (5YSRs) were calculated for various subsets of prognostic factors by the Kaplan--Meier method. Deaths of any cause observed during 5 postoperative years were counted as events in the survival analysis. SPSS Ver. 15 software (SPSS, Chicago, IL, USA) was used for statistical analyses. This nationwide registration program was approved by the ethics committee of the JGCA.

Results {#Sec3}
=======

The data were collected from 187 participating hospitals across the country. The geographical distribution of the registered patients among Japan's 47 prefectures is illustrated in Fig. [1](#Fig1){ref-type="fig"}. More than 1000 patients per year were registered in the prefectures of Tokyo and Osaka; on the other hand, the number of registered patients was less than 100 in 15 prefectures. The hospital volumes in the participating hospitals are indicated in Fig. [2](#Fig2){ref-type="fig"}. The median hospital volume was 66 patients per year.Fig. 1Geographical distribution of the registered patients Fig. 2Hospital volumes in the 187 participating hospitals

Data of 13067 patients who had undergone surgery in 2001 for primary gastric tumors were eventually accumulated. Of these, 88 patients with benign tumor or non-epithelial tumor were excluded from the analysis. Ninety-four patients who received endoscopic mucosal resection were also excluded. Data of 881 patients lacked essential items. Consequently, data of the remaining 12004 patients were used for the final analysis.

The results are shown in Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"}, [9](#Tab9){ref-type="table"}, [10](#Tab10){ref-type="table"}, [11](#Tab11){ref-type="table"}, [12](#Tab12){ref-type="table"}, [13](#Tab13){ref-type="table"}, [14](#Tab14){ref-type="table"}, [15](#Tab15){ref-type="table"}, [16](#Tab16){ref-type="table"}, [17](#Tab17){ref-type="table"}, [18](#Tab18){ref-type="table"}, [19](#Tab19){ref-type="table"}, [20](#Tab20){ref-type="table"}, [21](#Tab21){ref-type="table"}, [22](#Tab22){ref-type="table"}, [23](#Tab23){ref-type="table"}, [24](#Tab24){ref-type="table"}, [25](#Tab25){ref-type="table"}, [26](#Tab26){ref-type="table"}, [27](#Tab27){ref-type="table"}, and [28](#Tab28){ref-type="table"}; data in these Tables are for the total number of patients, survival rates by year, standard error of 5YSR, direct death within 30 postoperative days, numbers lost to follow-up within 5 years, 5-year survivors, and main causes of death (such as local and/or lymph node metastasis, peritoneal metastasis, liver metastasis, distant metastasis, recurrence at unknown site, other cancer and other disease). Figures [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, [6](#Fig6){ref-type="fig"}, [7](#Fig7){ref-type="fig"}, [8](#Fig8){ref-type="fig"}, [9](#Fig9){ref-type="fig"}, [10](#Fig10){ref-type="fig"}, [11](#Fig11){ref-type="fig"}, [12](#Fig12){ref-type="fig"}, [13](#Fig13){ref-type="fig"}, and [14](#Fig14){ref-type="fig"} show cumulative survival curves of patients stratified by essential categories.Table 3Survival outcomes of primary cancerNo. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKPrimary cancer1200486.478.774.171.169.10.495197665883091266374183349162530267*SE* standard error, *5YSR* 5-year survival rate, *DD* direct death, *Lost to follow up* lost to follow-up within 5 years, *Alive* 5-year survivors, *L* local recurrence and/or lymph node metastasis, *P* peritoneal metastasis, *H* liver metastasis, *M* distant metastasis, *R* recurrence at unknown site, *OC* other cancer, *OD* other disease, *UK* unknown Table 4Survival outcomes of resected cases and unresected casesNo. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKResected cases1126188.680.976.273.070.90.463187763542671040357161298155501251Unresected cases35023.09.87.15.65.31.32040143217612134301010 Table 5Survival outcomes by sexNo. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKMale782888.480.775.672.370.00.54713144348190646299112205138403173Female341988.981.177.574.673.00.816562199776392584993179778 Table 6Survival outcomes by ageNo. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUK\<4025789.982.080.379.478.42.704016533028410440--59323292.586.683.180.679.30.71251620956027458486613544860--79692487.980.174.971.669.20.6371129381818665125991182135322151≧8078878.564.358.653.148.72.0141782561884351329612346 Table 7Survival outcomes by tumor locationNo. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKU239986.076.771.367.565.31.01337012586923710749753213468M435192.287.183.380.878.90.6237602741652609043846516182L393689.481.477.174.271.90.721685223010830914152995517681Whole53263.744.733.725.823.42.06561042323017173432820*U* upper third, *M* middle third, *L* lower third of stomach Table 8Survival outcomes by macroscopic typeNo. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKType 0608597.595.793.791.890.30.41211434401204523233210021781Type 131879.166.761.756.554.62.944913612182871473611Type 2141984.873.066.562.559.71.411220669581271262959108140Type 3215176.560.852.447.845.11.121306760119425152621242511266Type 477962.141.930.023.420.41.510651333736311315473543Type 534086.874.367.462.659.52.84481661349167154157 Table 9Survival outcomes by histological diagnosisNo. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKpap36485.875.170.467.565.12.63641851127236138234tub1275295.291.187.985.383.50.75519181830554216365113748tub2299789.281.476.373.170.60.92053716516420715646744516057por1147682.572.467.864.963.71.31423873753174823040146939por2190381.469.763.459.556.61.21524488675401344486195955sig132593.288.084.581.279.41.242178551710821432123038muc23181.568.860.453.751.23.412410095451103196Adenosquamous carcinoma650.033.333.316.716.715.200102200100Squamous cell carcinoma560.030.00.00.00.00.001021010000Miscellaneous carcinoma4565.253.148.145.645.67.7041828722011*Pap* papillary adenocarcinoma, *tub1* tubular adenocarcinoma, well-differentiated type, *tub2* tubular adenocarcinoma, moderately differentiated type, *por1* poorly differentiated adenocarcinoma, solid type, *por2* poorly differentiated adenocarcinoma, non-solid type, *sig* signet-ring cell carcinoma, *muc* mucinous adenocarcinoma Table 10Survival outcomes by histological differentiationNo. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKDifferentiated type611391.785.481.278.376.10.6281120365410528922168123104320109Undifferentiated type493584.975.470.166.664.60.73472325781547371238916848177138Other type14481.675.371.968.468.44.1129746121142132 Table 11Survival outcomes by venous invasion (v)No. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKv0645395.491.588.686.284.50.523122843045425859367010126083v1260184.572.766.662.259.71.0173521276103365115531122912769v2134775.759.850.445.842.61.41716846371271954474168461v353959.444.535.732.230.82.15691283012385233442122 Table 12Survival outcomes by lymphatic invasion (ly)No. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKly0478397.295.393.391.489.90.511956338910482311358017754ly1260492.486.181.177.775.10.9133981606511878436374011550ly2204780.765.858.453.350.51.222271834102346134531031712364ly3148165.245.436.331.629.41.3161943349543811057110137753 Table 13Survival outcomes by depth of invasionNo. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKpT1(M)307198.196.995.093.592.20.55606224874417539843pT1(SM)266297.595.093.190.989.10.66500189811161911165110931pT2(MP)107193.488.784.080.978.31.331836751323311922176820pT2(SS)169587.074.767.663.260.61.217262817671481224865209947pT3(SE)227869.750.941.335.833.01.026264601132712140721481010297pT4(SI)41757.738.130.026.022.82.254577361343984042410*p* pathological finding, *M* mucosa or muscuralis musoca, *SM* submucosa, *MP* muscularis propria, *SS* subserosal, *SE* serosa, *SI* adjacent structures Table 14Survival outcomes by pT classificationNo. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKpT1573397.896.094.192.390.80.41111064146182023122310420774pT2276689.580.174.070.167.50.92044514928017115367873716767pT3227869.750.941.335.833.01.026264601132712140721481010297pT441757.738.130.026.022.82.254577361343984042410 Table 15Survival outcomes by lymph node metastasis (pN)No. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKpN0650897.094.792.590.689.00.42212404616189538164410924884pN1227484.772.366.261.358.31.11232210747830913946992311866pN2170372.152.841.435.833.41.219224439103442135691091310069pN342153.833.125.822.017.41.9433616013637283531315 Table 16Survival outcomes by liver metastasis (fH)No. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKfH01066589.982.678.174.972.70.55518066171249956216143268144482230fH130542.624.615.312.211.82.07282884813015255108*f* final finding Table 17Survival outcomes by peritoneal metastasis (fP)No. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKfP01030191.284.580.076.974.80.44917716131232628322143245148468213fP165849.027.019.314.712.41.41164662436330154912125 Table 18Survival outcomes by peritoneal cytology (CY)No. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKCY0410988.678.973.068.966.40.82467121571354031848212056185116CY165151.629.118.214.912.31.4473602333835156242516 Table 19Survival outcomes by distant metastasis (fM)No. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKfM01075289.482.077.374.272.10.55918176159233932331140278149479234fM121546.727.323.619.718.02.83213025721516162144 Table 20Survival outcomes by JGCA stageNo. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKStage IA499798.296.794.993.291.90.411983364661183148718158Stage IB145996.493.090.187.485.11.07267993928131115287817Stage II123793.085.079.775.773.11.371967362670442438146524Stage IIIA97585.871.261.255.251.01.791433954713750325366151Stage IIIB56276.655.343.936.033.42.15631534814131244023624Stage IV164953.932.222.418.315.81.02216120612262619962135117156 Table 21Survival outcomes by JGCA stage (4 classifications)No. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKStage I645697.895.893.891.990.30.41812504639153921142911525975Stage II123793.085.079.775.773.11.371967362670442438146524Stage III153782.465.454.948.244.51.3142065489527881569389775Stage IV164953.932.222.418.315.81.02216120612262619962135117156 Table 22Survival outcomes by TNM stageNo. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKStage IA479598.296.794.893.191.80.411951348961193138117557Stage IB149595.992.589.486.984.61.07290995112919819287719Stage II133392.184.277.472.970.51.3102017693492452847137727Stage IIIA87483.667.357.651.646.61.871343185113858214995145Stage IIIB35276.251.438.632.329.92.6339853510120142012116Stage IV163855.333.223.919.016.61.02115721912060518679128116865 Table 23Survival outcomes by TNM stage (4 classifications)No. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKStage I629097.795.793.591.790.10.41812414484174028113210925276Stage II133392.184.277.472.970.51.3102017693492452847137727Stage III122681.462.752.146.041.81.51017340386239783569107261Stage IV163855.333.223.919.016.61.02115721912060518679128116865 Table 24Survival outcomes by approachesNo. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKLaparotomy1053288.380.475.672.470.20.559175758692511002345154289147487231Thoraco-laparotomy11270.556.047.643.740.74.7383914191167044Laparoscopic39699.298.998.697.797.40.908730000001233Others2100.050.050.050.050.035.400100000010 Table 25Survival outcomes by operative proceduresNo. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKDistal gastrectomy668491.685.581.679.177.20.533117340961334121917512990267118Total gastrectomy337780.067.560.656.153.70.92551214271246121547515532179107Proximal gastrectomy44695.290.088.384.382.31.91603124961169218Pylorus-preserving27796.795.294.492.090.41.823222012302566Local excision/segmental resection33995.194.189.184.982.72.22692184420510207Mucosal resection13894.489.584.380.878.03.80318111101985 Table 26Survival outcomes by lymph node dissection (D)No. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKD081279.172.769.265.163.71.88153394178525430285224D1237185.176.972.970.468.31.0193401326482368331744613750D1+α136891.385.882.279.677.51.252927992669401528176814D1+β60594.890.787.284.983.51.62122391525105652610D2540390.782.877.574.071.80.62884031471345231668114253183134D339178.962.754.650.546.82.6030161308223181522010α, Lymph node No. 7 irrespective of the location of lesions, and additionally No. 8a in patients with lesions located in the lower third of the stomach; β, Lymph nodes No. 7, 8a, 9 Table 27Survival outcomes by involvement of the resection marginsNo. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKPM− and DM−1055089.582.377.774.672.50.55617846086232881338136258143466226PM+ and/or DM+33258.539.432.224.522.32.4634592211912193152011*PM* proximal margin, *DM* distal margin Table 28Survival outcomes by curative potential of gastric resectionNo. of patientsPostoperative survival rate (%)SE of 5YSRDDLost to follow upAliveMain cause of death1 year2 year3 year4 year5 yearLPHMROCODUKResection A703897.594.992.590.488.70.42013095006417252314910827199Resection B259385.070.762.156.353.11.0203641108121380151721193115790Resection C142050.328.719.715.513.41.0221451459856715255128106555*Resection A*, no residual disease with high probability of cure satisfying all of the following conditions: T1 or T2; N0 treated by D1, 2, 3 resection or N1 treated by D2, 3 resection; M0, P0, H0, CY0, and proximal and distal margins \>10 mm; *Resection B*, no residual disease but not fulfilling criteria for "Resection A"; *Resection C*, definite residual disease Fig. 3Kaplan--Meier survival for all 12004 patients with primary gastric cancer. *5YSR* 5-year survival rate Fig. 4Kaplan--Meier survival for resected cases and unresected cases Fig. 5Kaplan--Meier survival of the resected cases stratified by sex Fig. 6Kaplan--Meier survival of the resected cases stratified by age Fig. 7Kaplan--Meier survival of the resected cases stratified by tumor location. *W* whole stomach, *M* middle third, *L* lower third, *U* upper third of stomach Fig. 8Kaplan--Meier survival of the resected cases stratified by macroscopic type Fig. 9Kaplan--Meier survival of the resected cases stratified by depth of tumor invasion. *M* mucosa or muscuralis mucosa, *SM* submucosa, *MP* muscularis propria, *SS* subserosal, *SE* serosa, *SI* adjacent structures Fig. 10Kaplan--Meier survival of the resected cases stratified by pT classification Fig. 11Kaplan--Meier survival of the resected cases stratified by lymph node metastasis Fig. 12Kaplan--Meier survival of the resected cases stratified by Japanese Gastric Cancer Association (JGCA) stage Fig. 13Kaplan--Meier survival of the resected cases stratified by TNM stage Fig. 14Kaplan--Meier survival of the resected cases stratified by curative potential of gastric resection. *Resection A*, no residual disease with high probability of cure satisfying all of the following conditions: T1 or T2; N0 treated by D1, 2, 3 resection or N1 treated by D2, 3 resection; M0, P0, H0, CY0, and proximal and distal margins \>10 mm; *Resection B*, no residual disease but not fulfilling criteria for "Resection A"; *Resection C*, definite residual disease

The 5YSR in the 12004 patients with primary gastric cancer was 69.1% (Table [3](#Tab3){ref-type="table"}; Fig. [3](#Fig3){ref-type="fig"}). Within 5 postoperative years, 1976 patients were lost to follow-up; the follow-up rate was 83.5%. Of the 12004 patients, 11261 underwent gastric resection; 350 were unresected; and in 393 the type of surgery was not specified. Accordingly, the resection rate was 97.0% (11261/11611). Sixty-three of the 11261 patients who had undergone gastrectomy died within 30 postoperative days; the direct death rate was 0.6% (Table [4](#Tab4){ref-type="table"}; Fig. [4](#Fig4){ref-type="fig"}).

The most frequent cause of death in patients who had received gastrectomy was peritoneal metastasis (*n* = 1040), followed, in descending order, by other diseases (*n* = 501), liver metastasis (*n* = 357), recurrence at an unknown site (*n* = 298), and local recurrence including node metastasis (*n* = 267).

The proportion of male patients was 69.6% and their 5YSR was lower than that of female patients (*P* \< 0.01; Table [5](#Tab5){ref-type="table"}; Fig. [5](#Fig5){ref-type="fig"}). The proportion of patients who were more than 80 years old was 7.0%, and their 5YSR was 48.7% (Table [6](#Tab6){ref-type="table"}; Fig. [6](#Fig6){ref-type="fig"}). Upper-third gastric cancer accounted for 21.4% of the cases, and the 5YSR (65.3%) of patients with cancer at this site was lower than that for the middle- and lower-third cancers (*P* \< 0.001; Table [7](#Tab7){ref-type="table"}; Fig. [7](#Fig7){ref-type="fig"}). The proportion of patients with type 4 cancer was 7.0%, and their 5YSR was markedly low, at 20.4% (*P* \< 0.001; Table [8](#Tab8){ref-type="table"}; Fig. [8](#Fig8){ref-type="fig"}). In regard to the histological type, the 5YSR of patients with undifferentiated type, including poorly differentiated adenocarcinoma, signet-ring cell carcinoma, and mucinous adenocarcinoma, was 64.6%. The undifferentiated type showed a poorer prognosis than the differentiated type (*P* \< 0.001; Tables [9](#Tab9){ref-type="table"}, [10](#Tab10){ref-type="table"}). The grade of venous invasion (v0--v3) and that of lymphatic invasion (ly0--ly3) showed significant correlations with prognosis (*P* \< 0.001; Tables [11](#Tab11){ref-type="table"}, [12](#Tab12){ref-type="table"}).

There was a high incidence of early-stage cancer, as indicated in Tables [13](#Tab13){ref-type="table"} and [14](#Tab14){ref-type="table"} and Figs. [9](#Fig9){ref-type="fig"} and [10](#Fig10){ref-type="fig"}. The proportion of pathological T1 (pT1; mucosal or submucosal) cancer was 51.2%. The 5YSR of this population was 90.8%, and the primary cause of death was not cancer recurrence (*n* = 96), but other diseases (*n* = 207).

Peritoneal washing cytology (CY) was carried out for 3481 of 5857 patients with T2, T3, and T4 cancer (59.4%). The 5YSR of cytology-positive patients (CY1) was 12.3%, which corresponded with that of the patients with peritoneal metastasis (P1) (Tables [17](#Tab17){ref-type="table"}, [18](#Tab18){ref-type="table"}).

The 5YSRs of the patients stratified by the JGCA staging system were 91.9% for stage IA, 85.1% for stage IB, 73.1% for stage II, 51.0% for stage IIIA, 33.4% for stage IIIB, and 15.8% for stage IV. These JGCA 5YSRs seemed to correlate well with the TNM 5YSRs (Tables [20](#Tab20){ref-type="table"}, [21](#Tab21){ref-type="table"}, [22](#Tab22){ref-type="table"}, [23](#Tab23){ref-type="table"}; Figs. [12](#Fig12){ref-type="fig"}, [13](#Fig13){ref-type="fig"}).

In regard to the operative procedure, the proportion of patients who underwent laparoscopic gastrectomy was 3.6%, and their 5YSR was 97.4%. Laparoscopic surgery was carried out mainly in patients with early gastric cancer. Only 1.0% of the patients were treated by thoraco-laparotomy, and their 5YSR was 40.7%. Thoraco-laparotomy was carried out in patients with gastric cardia cancer invading the esophagus (Table [24](#Tab24){ref-type="table"}). Thirty percent of the patients underwent total gastrectomy, and their 5YSR was 53.7%. The proportion of patients treated by modified surgery such as proximal gastrectomy, pylorus-preserving gastrectomy, segmental gastrectomy, and local resection was 9.4% (Table [25](#Tab25){ref-type="table"}). D0, D1, D1+α, and D1+β dissections were carried out in 7.4, 21.7, 12.5, and 5.5% of the patients, respectively. According to the JGCA gastric cancer treatment guidelines \[[@CR7], [@CR8]\], D1+α dissection with modified gastrectomy was indicated for T1(M)N0 tumors and T1(SM)N0 differentiated tumors \<1.5 cm in diameter, while D1+β dissection with modified gastrectomy was indicated for T1(SM)N0 undifferentiated tumors, T1(SM)N0 differentiated tumors larger than 1.6 cm, T1(M)N1 tumors, and T1(SM)N1 tumors \<2.0 cm. D0 and D1 dissections were carried out mainly in patients with non-curative factors or poor surgical risks. D2 lymph node dissection was carried out in 49.3% of the patients and the risk of direct death in those with D2 gastrectomy was 0.5% (28/5403; Table [26](#Tab26){ref-type="table"}).

The curative potential of gastric resection was an important prognostic factor. The proportion of patients with a high probability of cure (resection A) was 63.7%, and their 5YSR was 88.7%. On the other hand, the proportion of patients with definite residual tumor (resection C) was 12.8%, and their 5YSR was 13.4% (Table [28](#Tab28){ref-type="table"}; Fig. [14](#Fig14){ref-type="fig"}).

Discussion {#Sec4}
==========

The data presented in this report were collected from 187 hospitals in Japan. The number of new patients who were diagnosed with gastric cancer in 2001 was estimated to be 107726 \[[@CR9]\]. Accordingly, the 11261 patients registered by this program corresponded to approximately 10% of the population affected by gastric cancer in Japan. Even though these patients may not represent the average features of gastric cancer, this article is considered to be the largest report for the past 10 years clarifying the trends of gastric cancer.

The reliability of the results in this report depends on the quality of data accumulated in the JGCA database. As the algorithms of the JGCA staging system were rather complicated, the error checking system on the data entry screen did not work perfectly. In several categories, such as lymph node metastasis (N), the JGCA code could not convert to the TNM code automatically. A few "bugs" in the software were revealed just after we had analyzed thousands of data records. Therefore, the registration committee had to make great efforts to cleanse and validate the raw data sent to the data center from participating hospitals.

As compared with our archived data of 7935 patients treated in 1991 \[[@CR1]\], though the proportions of each stage were similar, the direct death rate had significantly improved, dropping from 1.0 to 0.6% (*P* \< 0.001); the proportion of patients aged more than 80 years old had increased, from 4.5 to 7.0% (*P* \< 0.001); and the 5YSR of stage IV had improved, from 9.0 to 15.8% (*P* \< 0.05). These data suggest that, in this decade, the treatment results may have improved in patients with advanced disease and in older patients.

However, these data were retrospectively collected, 7 years after surgery. We had legal difficulties in registering personal information, which was essential for long-term and prospective follow-up. The overall follow-up rate in our program was 83.5%, as already mentioned. A lower follow-up rate is generally considered to show misleading results of higher survival rates in patients with advanced disease. The Japanese Association of Clinical Cancer Centers (consisting of 25 cancer center hospitals) has reported that their follow-up rate was 98.5%, and the 5YSRs of 9980 patients who underwent surgery from 1997 to 2000 were 90.4% for TNM stage I, 67.8% for stage II, 43.3% for stage III, and 9.3% for stage IV \[[@CR10]\]. On the other hand, our 5YSR in stage IV patients was 16.6% (Table [23](#Tab23){ref-type="table"}). We might have overestimated our 5YSR in stage IV patients, but we found that the follow-up rate increased as the stage advanced; the follow-up rate of stage IV patients was 90.4% (Table [29](#Tab29){ref-type="table"}). Of the 187 participating hospitals, 114 hospitals achieved high follow-up rates of 90% or more for stage IV patients. Therefore, the 5-year follow-up rates and 5YSRs in these 114 hospitals were calculated for reference. The mean follow-up rate for stage IV patients in these 114 selected hospitals was 97.7% and their 5YSR was 15.9% (Table [30](#Tab30){ref-type="table"}). These data suggest that the lower follow-up rate in our program may not have serious effects on the 5YSRs. Although the correlation between follow-up rate and survival rate is complicated, we need to greatly improve our follow-up system to evaluate our survival rates more accurately.Table 29Five-year follow-up rates stratified by TNM stageNo. of patientsLost to follow upFUR (%)Stage I6290124180.3Stage II133320184.9Stage III122617385.9Stage IV163815790.4Total10487177283.1*FUR* 5-year follow-up rate Table 30Follow-up rates and survival rates stratified by TNM stage in 187 participating hospitals and 114 selected hospitalsTNM stage187 Participating hospitals114 Selected hospitalsNo. of patientsFUR (%)5YSR (%)No. of patientsFUR (%)5YSR (%)Stage IA479580.291.8340184.091.3Stage IB149580.684.6100084.282.5Stage II133384.970.593889.670.3Stage IIIA87484.746.660893.145.2Stage IIIB35288.929.924393.830.8Stage IV163890.416.6119697.715.9The 114 hospitals were selected on the criterion of achieving high follow-up rate of 90% or more for stage IV patients

This is the first nationwide report in which the JGCA refers to peritoneal washing cytology (CY). CY was conducted in 3481 (59.4%) of 5857 patients with T2, T3, or T4 cancer. The 5YSR of CY-positive (CY1) patients was 12.3% and their 5YSR was as poor as that of patients with peritoneal metastasis (P1; 12.4%). Although CY was not carried out commonly in 2001, it was regarded as a significant and independent prognostic factor.

The JGCA restarted a nationwide registration program after an inactive period of 10 years. The most urgent priority of this program was to report detailed 5YSRs in patients who had received a gastrectomy. Therefore, the structure of the database was required to be simple and the number of registration items was kept to a minimum. We are now planning to register more items concerning remnant gastric cancer, chemotherapy, and endoscopic submucosal dissection by upgrading the data entry software. We will continue our efforts to collect qualified data annually.

Appendix: Member hospitals {#Sec5}
==========================

Data of gastric cancer patients in this report were collected from the surgical or gastrointestinal departments of the following 187 hospitals (in alphabetical order).

Aichi Cancer Center Aichi Hospital, Aichi Cancer Center Hospital, Akashi Municipal Hospital, Aomori City Hospital, Asahikawa Medical University, Cancer Institute Hospital, Chiba Cancer Center, Chiba University Hospital, Dokkyo Medical University, Ebina General Hospital, Fuchu Hospital, Fujita Health University (Banbuntane Houtokukai Hospital), Fujita Health University Hospital, Fukui Red Cross Hospital, Fukui Saiseikai Hospital, Fukuoka University Chikushi Hospital, Fukuoka University Hospital, Fukushima Medical University Hospital, Gunma Prefectural Cancer Center, Gunma University Graduate School of Medicine (Department of General Surgical Science), Gunma University Graduate School of Medicine (Department of Thoracic Visceral Organ Surgery), Hachioji Digestive Disease Hospital, Hakodate Goryoukaku Hospital, Hakodate Municipal Hospital, Hamamatsu University School of Medicine, Hamanomachi Hospital, Health Insurance Naruto Hospital, Higashiosaka City General Hospital, Himeji Central Hospital, Hirakata City Hospital, Hiroshima City Hospital, Hiroshima Prefectural Hospital, Hiroshima University Hospital, Hitachi General Hospital, Hoshigaoka Koseinenkin Hospital, Hyogo Cancer Center, Hyogo Prefectural Nishinomiya Hospital, Ibaraki Prefectural Central Hospital, Ibaraki Seinan Medical Center Hospital, Ichinomiya Municipal Hospital, Imamura Hospital, Iwate Prefectural Central Hospital, Iwate Prefectural Isawa Hospital, Iwate Prefectural Kamaishi Hospital, JA Hiroshima Kouseiren Hiroshima General Hospital, Jichi Medical University Hospital, Jikei University School of Medicine (Aoto Hospital), Kagawa University Hospital, Kakogawa Municipal Hospital, Kanagawa Cancer Center, Kanazawa Medical University Hospital, Kawasaki Medical School Hospital, Kawasaki Municipal Hospital, Keio University School of Medicine, Keiyukai Sapporo Hospital, Kimitsu Chuo Hospital, Kinki Central Hospital, Kinki University School of Medicine (Nara Hospital), Kiryu Kosei General Hospital, Kitakyushu Municipal Medical Center, Kitasato Institutional Hospital, Kitasato University East Hospital, Kobe City Medical Center General Hospital, Kobe University Hospital, Koga General Hospital, Kokura Memorial Hospital, Kouchi Medical School Hospital, Kumamoto Regional Medical Center, Kumamoto University Hospital, Kurashiki Central Hospital, Kurobe City Hospital, Kushiro Rosai Hospital, Kyorin University Hospital, Kyoto Prefectural University of Medicine, Kyoto Prefectural Yosanoumi Hospital, Kyoto University Hospital, Kyushu University Hospital, Matsue City Hospital, Matsushita Memorial Hospital, Matsuyama Shimin Hospital, Minami Tohoku Hospital, Misawa City Hospital, Mitoyo General Hospital, Mitsui Memorial Hospital, Miyagi Cancer Center, Muroran General Hospital, Musashino Red Cross Hospital, Nagahama City Hospital, Nagano Municipal Hospital, Nagaoka Chuo General Hospital, Nagoya City University Hospital, Nagoya University Hospital, Nanpuh Hospital, Nara Medical University Hospital, Narita Red Cross Hospital, National Defense Medical College, National Kyushu Cancer Center, NHO Ciba Medical Center, NHO Ibusuki Hospital, NHO Kasumigaura Medical Center, NHO Kobe Medical Center, NHO Nagasaki Medical Center, NHO Osaka Medical Center, NHO Sendai Medical Center, NHO Shikoku Cancer Center, NHO Tokyo Medical Center, Niigata Cancer Center Hospital, Niigata Prefectural Shibata Hospital, Niigata University Medical and Dental Hospital, Nippon Medical School Chiba Hokusoh Hospital, Nippon Medical School Musashikosugi Hospital, Nippon Medical School, NTT West Osaka Hospital, Obihiro Tokushukai Hospital, Oita Red Cross Hospital, Oita University Hospital, Okayama Saiseikai General Hospital, Okayama University Hospital, Okitama Public General Hospital, Onomichi Municipal Hospital, Osaka City University Hospital, Osaka General Medical Center, Osaka Kouseinenkin Hospital, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka Red Cross Hospital, Otsu Municipal Hospital, Otsu Red Cross Hospital, Ryukyu University School of Medicine, Saga University Hospital, Sagamihara Kyodo Hospital, Saiseikai Fukuoka General Hospital, Saiseikai Maebashi Hospital, Saiseikai Niigata Daini Hospital, Saiseikai Noe Hospital, Saitama Medical Center, Saitama Red Cross Hospital, Saitama Social Insurance Hospital, Sakai Municipal Hospital, Saku Central Hospital, Sapporo Social Insurance General Hospital, Sayama Hospital, Seirei Hamamatsu General Hospital, Seirei Mikatahara General Hospital, Self-defense Forces Central Hospital, Sendai Open Hospital, Sendai Red Cross Hospital, Shiga Medical Center for Adults, Shiga University of Medical Science, Showa General Hospital, Showa University Toyosu Hospital, Social Insurance Central General Hospital, Social Insurance Kinan Hospital, St. Luke's International Hospital, Suita Municipal Hospital, Surugadai Nihon University Hospital, Tochigi Cancer Center, Toho University Ohashi Medical Center, Tokushima Municipal Hospital, Tokushima University Hospital, Tokyo Dental College Ichikawa General Hospital, Tokyo Medical University, Tokyo Metropolitan Bokutoh Hospital, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo Metropolitan Police Hospital, Tokyo Women's Medical University (Institute of Gastroenterology), Tokyo Women's Medical University Hospital (Department of Surgery 2), Tokyo Women's Medical University Medical Center East, Tonami General Hospital, Toranomon Hospital, Tottori University Hospital, Toyama University Hospital, Tsuchiura Kyodo General Hospital, Tsuruoka Municipal Shonai Hospital, University of Fukui Hospital, University of Miyazaki Hospital, University of Tokyo Hospital, University of Yamanashi Hospital, Wakayama Medical University, Yamagata Prefectural Central Hospital, Yamagata Prefectural Kahoku Hospital, Yamagata University Hospital, Yamaguchi Rousai Hospital, Yamanashi Prefectural Central Hospital, Yao Municipal Hospital, Yodogawa Christian Hospital, Yokohama City University Medical Center, Yuai Memorial Hospital.

All the authors belong to the Registration Committee of the Japanese Gastric Cancer Association.
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